Northeast Pharmaceutical Group Yönetim

Yönetim kriter kontrolleri 2/4

Northeast Pharmaceutical Group CEO'su Zhou Kai, May2019 tarihinde atandı, in görev süresi 5.5 yıldır. şirketin hisselerinin 0.3% doğrudan sahiptir ve bu hisselerin değeri CN¥ 20.93M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.8 yıl ve 5 yıldır.

Anahtar bilgiler

Zhou Kai

İcra Kurulu Başkanı

CN¥1.8m

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	5.5yrs
CEO sahipliği	0.3%
Yönetim ortalama görev süresi	1.8yrs
Yönetim Kurulu ortalama görev süresi	5yrs

Son yönetim güncellemeleri

Recent updates

Northeast Pharmaceutical Group's (SZSE:000597) Weak Earnings May Only Reveal A Part Of The Whole Picture

Oct 30

It's A Story Of Risk Vs Reward With Northeast Pharmaceutical Group Co., Ltd. (SZSE:000597)

Aug 07

These 4 Measures Indicate That Northeast Pharmaceutical Group (SZSE:000597) Is Using Debt Safely

May 25

Northeast Pharmaceutical Group (SZSE:000597) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Apr 05

CEO

Zhou Kai (60 yo)

5.5yrs

Görev süresi

CN¥1,824,100

Tazminat

Mr. Zhou Kai serves as a General Manager of Northeast Pharmaceutical Group Co., Ltd. since May 8, 2019 and serves its Non-Independent Director since November 29, 2020. He served as a Vice President of Nort...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Zhou Kai	GM & Director	5.5yrs	CN¥1.82m	0.30% CN¥ 20.9m
Jialun Song	Financial Director & Secretary	1.8yrs	CN¥2.14m	0.022% CN¥ 1.6m
Xiao Feng	Deputy General Manager	less than a year	CN¥894.30k	Veri yok

1.8yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim: 000597 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Zhou Kai	GM & Director	4yrs	CN¥1.82m	0.30% CN¥ 20.9m
Demin Han	Independent Director	6.3yrs	CN¥150.00k	Veri yok
Zhaochun Tan	Non-Independent Director	3yrs	Veri yok	Veri yok
Chengren Huang	Non-Independent Director	6.3yrs	Veri yok	0.23% CN¥ 16.0m
Xinhua Ao	Non-Independent Director	6.3yrs	Veri yok	0.23% CN¥ 16.0m
Guodong Wang	Independent Director	6.3yrs	CN¥150.00k	Veri yok
Hui Yao	Independent Director	6.3yrs	CN¥150.00k	Veri yok
Youguang Shang	Independent Director	4.1yrs	CN¥150.00k	Veri yok
Jianmin Guo	Chairman of the Board	3.1yrs	CN¥2.07m	0.22% CN¥ 15.8m
Zhihua Huang	Non-Independent Director	3yrs	Veri yok	0.070% CN¥ 5.0m
Baidan Zhan	Chairman of the Supervisory Board	5.9yrs	Veri yok	Veri yok
Hai Tian	Director	1.2yrs	Veri yok	Veri yok

5.0yrs

Ortalama Görev Süresi

59yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 000597 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5 yıldır).

Northeast Pharmaceutical Group Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 19, 2024

High number of new directors

High number of new directors

High number of new directors

High number of new directors

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 06, 2021

Recent updates

Northeast Pharmaceutical Group's (SZSE:000597) Weak Earnings May Only Reveal A Part Of The Whole Picture

Third quarter 2024 earnings released: EPS: CN¥0.036 (vs CN¥0.059 in 3Q 2023)

Northeast Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Investor sentiment improves as stock rises 19%

New minor risk - Earnings quality

Second quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.045 in 2Q 2023)

New minor risk - Share price stability

Investor sentiment improves as stock rises 22%

It's A Story Of Risk Vs Reward With Northeast Pharmaceutical Group Co., Ltd. (SZSE:000597)

Northeast Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

These 4 Measures Indicate That Northeast Pharmaceutical Group (SZSE:000597) Is Using Debt Safely

Dividend of CN¥0.10 announced

Northeast Pharmaceutical Group Co., Ltd. Implements 2023 Final Cash Profit Distribution Plan, Payable on 23 May 2024

New minor risk - Earnings quality

First quarter 2024 earnings released: EPS: CN¥0.04 (vs CN¥0.049 in 1Q 2023)

Northeast Pharmaceutical Group (SZSE:000597) Is Posting Promising Earnings But The Good News Doesn’t Stop There

Full year 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.25 in FY 2022)

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 19, 2024

Investor sentiment deteriorates as stock falls 18%

Northeast Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

High number of new directors

Third quarter 2023 earnings released: EPS: CN¥0.059 (vs CN¥0.011 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.045 (vs CN¥0.033 in 2Q 2022)

Now 21% undervalued after recent price drop

Northeast Pharmaceutical Group Co., Ltd. to Report First Half, 2023 Results on Aug 23, 2023

Now 21% undervalued after recent price drop

Northeast Pharmaceutical Group Co., Ltd. Announces 2022 Final Cash Profit Distribution Plan, Payable on 16 May 2023

Full year 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.07 in FY 2021)

Now 21% undervalued

Now 21% undervalued

Now 21% undervalued

Investor sentiment improved over the past week

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.011 (vs CN¥0.026 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.033 (vs CN¥0.016 in 2Q 2021)

High number of new directors

Northeast Pharmaceutical Group Co., Ltd. Proposes Final Dividend for the Year 2021, Payable on 27 May 2022

First quarter 2022 earnings released: EPS: CN¥0.051 (vs CN¥0.029 in 1Q 2021)

Northeast Pharmaceutical Group Co., Ltd. Approves the Profit Distribution for 2021

Full year 2021 earnings released: EPS: CN¥0.07 (vs CN¥0.01 in FY 2020)

Northeast Pharmaceutical Group Co., Ltd. Proposes Cash Dividend for 2021

High number of new directors

Third quarter 2021 earnings released: CN¥0.026 loss per share (vs CN¥0.042 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.016 (vs CN¥0.063 in 2Q 2020)

Northeast Pharmaceutical Group Co., Ltd. Announces Final Cash Dividend of A Shares, Payable on 27 May 2021

First quarter 2021 earnings released: EPS CN¥0.029 (vs CN¥0.013 loss in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.01 (vs CN¥0.13 in FY 2019)

Northeast Pharmaceutical Group Co., Ltd. Proposes Final Cash Dividend for the Year 2020

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 06, 2021

Northeast Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 17, 2021

New 90-day low: CN¥4.86

New 90-day low: CN¥5.03

New 90-day low: CN¥5.37

New 90-day low: CN¥5.39

Third quarter earnings released

Northeast Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020

Jiangxi Fangda Steel Technology Co., Ltd. completed the acquisition of an additional 10% stake in Northeast Pharmaceutical Group Co., Ltd. (SZSE:000597) for approximately CNY 890 million.

Northeast Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 2 billion in funding from Joyvio Group Co., Ltd., Liaoning Fangda Group Industrial Co., Ltd., and other investors

First half earnings released

New 90-day high - CN¥6.15

New 90-day high - CN¥6.02

Northeast Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri